iofrequency tumor ablation: challenges and opportunities--part II. Journal of vascular and interventional radiology : JVIR. 2001;12(10):1135-48.
12. Facciorusso A, Del Prete V, Antonino M, Crucinio N, Neve V, Di Leo A, et al. Post-recurrence survival in hepatocellular carcinoma after percutaneous radiofrequency ablation. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2014;46(11):1014-9.
13. Lau WY, Lai EC. The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Annals of surgery. 2009;249(1):20-5.
14. Peng ZW, Zhang YJ, Chen MS, Liang HH, Li JQ, Zhang YQ, et al. Risk factors of survival after percutaneous radiofrequency ablation of hepatocellular carcinoma. Surgical oncology. 2008;17(1):23-31.
15. Gervais DA, Arellano RS. Percutaneous tumor ablation for hepatocellular carcinoma. AJR American journal of roentgenology. 2011;197(4):789-94.
16. Yamamoto J, Okada S, Shimada K, Okusaka T, Yamasaki S, Ueno H, et al. Treatment strategy for small hepatocellular carcinoma: comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatology (Baltimore, Md). 2001;34(4 Pt 1):707-13.
17. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut. 2005;54(8):1151-6.
18. Yamada K, Izaki K, Sugimoto K, Mayahara H, Morita Y, Yoden E, et al. Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. International journal of radiation oncology, biology, physics. 2003;57(1):113-9.
19. Tavernier J, Fagnoni P, Chabrot P, Guiu B, Vadot L, Aho S, et al. Comparison of two transarterial chemoembolization strategies for hepatocellular carcinoma. Anticancer research. 2014;34(12):7247-53.
20. Takayasu K, Arii S, Ikai I, Kudo M, Matsuyama Y, Kojiro M, et al. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR American journal of roentgenology. 2010;194(3):830-7.
21. Poon RT, Ngan H, Lo CM, Liu CL, Fan ST, Wong J. Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence. Journal of surgical oncology. 2000;73(2):109-14.
22. Vogl TJ, Naguib NN, Nour-Eldin NE, Rao P, Emami AH, Zangos S, et al. Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. European journal of radiology. 2009;72(3):505-16.
23. Daniels JR. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR American journal of roentgenology. 2011;196(2):W220.
24. Li G, Dong S, Qu J, Sun
